Arnaud Scherpereel
0000-0002-7607-1863
Publication & Citation Trends
Most Cited Works
Publications
453 total
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer PDF
Cited by 603
OpenAlex
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Cited by 1,335
OpenAlex
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial PDF
Cited by 1,155
OpenAlex
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) PDF
Cited by 784
OpenAlex
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma PDF
Cited by 256
OpenAlex
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial PDF
Cited by 453
OpenAlex
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Cited by 423
OpenAlex
Research Topics
Occupational and environmental lung diseases
(156)
Pleural and Pulmonary Diseases
(124)
Lung Cancer Treatments and Mutations
(105)
Lung Cancer Diagnosis and Treatment
(74)
Lung Cancer Research Studies
(56)
Frequent Co-Authors
Affiliations
Centre National de la Recherche Scientifique
All India Institute of Medical Sciences Raipur
Université Libre de Bruxelles
Bayer (United States)
Inserm